MarketCap
Facebook
X
TelegramPandion Therapeutics, Inc. Market Cap | PAND
As of November 08, 2026 Pandion Therapeutics, Inc. has a market cap of $ 1.77 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Pandion Therapeutics, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 419 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 419 M | 419 M | 419 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Neos Therapeutics, Inc.
NEOS
|
80.6 M | - | -2.54 % | $ 57.2 M |  USA |
 |
Xencor
XNCR
|
892 M | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
759 M | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
236 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
262 M | - | -10.74 % | $ 89.9 M | USA |
 |
Xenetic Biosciences
XBIO
|
4.37 M | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
1.23 B | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
1.1 B | - | - | $ 1.94 B |  Canada |
 |
Exicure
XCUR
|
29 M | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
273 B | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
6.89 B | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
855 M | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
1.02 B | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
18.2 M | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
790 M | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
2.38 B | $ 39.02 | 3.56 % | $ 3.09 B | Canada |
 |
Leap Therapeutics
LPTX
|
43.8 M | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
845 M | $ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
70 M | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
2.78 B | $ 3.6 | -9.22 % | $ 789 M | Britain |
 |
Daré Bioscience
DARE
|
16.9 M | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
187 M | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
386 M | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
12 B | $ 15.16 | 6.76 % | $ 13 B | China |
 |
Aptorum Group Limited
APM
|
6.69 M | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
142 M | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
2.03 B | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
45.1 K | $ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
50.7 M | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
9.41 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
3.04 B | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
924 M | $ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
999 M | $ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
36.6 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
14.8 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
29.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
2.77 B | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
1.61 M | - | 1083.1 % | $ 745 M | USA |